perpetuity. It is made available under a CC-BY-NC 4.0 International license.

### **Estimating the Treatment Effects of Multiple Drug** Combinations on Multiple Outcomes in Hypertension 2

Ruogi Liu<sup>1</sup>, Lang Li<sup>2</sup>, and Ping Zhang<sup>1,2,3,\*</sup> 3

- <sup>1</sup>Department of Computer Science and Engineering. The Ohio State University, 2015 Neil Ave,
- Columbus OH 43210, USA. 5
- <sup>2</sup>Department of Biomedical Informatics. The Ohio State University, 1800 Cannon Drive, 6
- Columbus OH 43210, USA. 7
- <sup>3</sup>Translational Data Analytics institute. The Ohio State University, 1760 Neil Ave, Columbus OH 8
- 43210, USA. 9
- Corresponding Author & Lead Contact: zhang.10631@osu.edu 10

### Summary 11

Hypertension poses a significant global health challenge, and its management is often complicated by the 12 complexity of treatment strategies involving multiple drug combinations and the need to consider multiple 13 outcomes. Traditional treatment effect estimation (TEE) methods struggle to address this complexity, as 14 they typically focus on binary treatments and binary outcomes. To overcome these limitations, we intro-15 duce **METO**, a novel framework designed for TEE in the context of multiple drug combinations and multiple 16 outcomes. METO employs a multi-treatment encoding mechanism to handle multiple drug combinations 17 and their sequences effectively, and differentiates between effectiveness and safety outcomes by explicitly 18 learning the outcome type when predicting the treatment outcomes. Furthermore, to address confounding 19 bias in outcome prediction, we employ an inverse probability weighting method tailored for multiple treat-20 ments, assigning each patient a balance weight derived from their propensity score against different drug 21 combinations. Our comprehensive evaluation using a real-world patient dataset demonstrates that **METO** 22 outperforms existing TEE methods, with an average improvement of 5.0% in area under the precision-23 recall curve and 6.4% in influence function-based precision of estimating heterogeneous effects. A case 24 study demonstrates that our method successfully identifies personalized optimal antihypertensive dual 25 regimens, achieving maximal efficacy and minimal drug-related safety risks. This showcases its potential 26 for improving treatment strategies and outcomes in hypertension management. 27

### **Keywords** 28

Treatment effect estimation, deep learning, real-world data, hypertension, multiple drug combinations, 29 precision medicine 30

### Introduction 31

Hypertension is a major global health issue, responsible for around 7 million deaths and 57 million dis-32 abilities annually<sup>[1]</sup>. However, optimal blood pressure control remains elusive for roughly 70% of patients, 33 primarily due to inadequate implementation of combination therapies<sup>2</sup>. The challenge lies in selecting 34 effective antihypertensive treatment strategies<sup>[3]</sup>, including the choice between starting with monotherapy 35 and gradually adding another drug (stepped-care) or beginning with a drug combination<sup>[4]5]</sup>. 36

This introduces a pivotal medical question: "How can we determine the most effective antihyperten-37 sive drug combinations (treatments) to improve hypertension-related conditions (outcomes)?" Tackling 38 this question requires an exploration into the complex landscape of treatment options, encompassing a 39 variety of drug combinations and sequences. Moreover, the imperative for a thorough evaluation of treat-40 ments underscores the inherent tension between effectiveness and safety outcomes in hypertension<sup>6</sup>, 41 42

#### perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Treatment effect estimation (TEE), which identifies the causal effects of *treatments* on the patient 43 outcomes, can be leveraged to address the above complex question of optimizing antihypertensive drug 44 combinations. However, existing TEE approaches, designed predominantly for binary treatments and 45 binary outcomes<sup>8-10</sup>, struggle with multiple treatments and multiple outcomes. Some approaches<sup>111-14</sup> 46 extend existing models for multiple treatments by directly increasing treatment arms, thus facing efficiency 47 and generalizability challenges<sup>15</sup>. Others improve adaptability using unified treatment embeddings for 48 multiple treatments<sup>1516</sup>. Nevertheless, significant challenges remain in applying these methods to TEE 49 with multiple treatments and multiple outcomes, particularly for antihypertensive drug combinations. 50

First, existing methods<sup>1316</sup> typically treat all treatments uniformly, without utilizing the nuanced details 51 of each. This lack of granular differentiation limits their practicality, especially in the studied scenarios 52 where the combination and sequential administration of drugs are crucial. Second, while some stud-53 ies<sup>17-19</sup> have explored TEE in the context of multiple outcomes, they are mainly designed for randomized 54 controlled trials without adjustment for confounding bias, and more importantly, fail to differentiate between 55 outcome types (i.e., therapeutic effectiveness versus adverse effects). In addition, different outcomes can 56 have different relationships with the covariates and treatments. Failing to consider such various rela-57 tionships may lead to confounding bias and inaccurate treatment effects estimation. Finally, there is a 58 noticeable gap in the literature regarding the comprehensive treatment effect assessment tool that facili-59 tates clinical decision-making. 60

To address these challenges, we propose a novel framework, called METO, to estimate the treatment 61 effects of **M**ultipl**E** drug combinations on mul**T**iple **O**utcomes for identifying optimal antihypertensive drug 62 combinations (see Fig. 1). First, we address the complexities of multiple drug combinations through the 63 proposed multi-treatment modeling. This mechanism processes the detailed information of drug com-64 binations and administration sequences independently, before synthesizing these elements via a deep 65 fusion layer. Second, we leverage the specific outcome type information as additional guidance to differ-66 entiate between effectiveness and safety outcomes, enhancing the accuracy of outcome prediction. In 67 addition, to address confounding bias in outcome prediction, we employ an inverse probability weight-68 ing method tailored for multiple treatments, assigning each patient a balance weight derived from their 69 propensity score against different drug combinations. Our comprehensive evaluation shows that METO 70 outperforms existing treatment effect estimation methods and successfully identifies personalized optimal 71 drug combinations with beneficial effects and reduced safety risks. 72

<sup>73</sup> Our contributions are summarized as follows:

• **Problem.** We address the challenge of TEE in hypertension management, focusing on multiple drug combinations and their impact on both effectiveness and safety outcomes.

Method. We propose METO, a novel method that incorporates multi-treatment encoding and explicit
 outcome-type learning to handle complex drug combinations and differentiate between effectiveness
 and safety outcomes.

Experiments. We validate METO's superior performance against existing TEE methods using a large scale real-world dataset and demonstrate its practical efficacy through a case study on personalized
 drug combination recommendation.

# 82 **Results**

## **Overall Framework**

We develop an end-to-end treatment effect estimation framework that can be utilized for recommending optimal drug combinations for patients with hypertension. As shown in Fig. 1, the patient medical records are extracted from an observational database and then processed into drug combination cohorts for comparing treatment effectiveness. The treatment effects are estimated with the proposed **METO**, which is designed specifically for the scenario of multiple treatments and multiple outcomes. Finally, optimal drug combinations are suggested by assessing the treatment effects across both effectiveness and safety outcomes.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

# 91 Dataset

We collect data on approximately 130 million patients from the MarketScan Commercial Claims and En-92 counters (CCAE)<sup>1</sup> database, covering the period from 2012 to 2021. This dataset contains individual-level, 93 de-identified healthcare claims information from employers, health plans, and hospitals. We extract more 94 than 19 million patients who are diagnosed with hypertension (Appendix Table A1). Within this patient 95 cohort, we identify more than 11 million patients who have at least one risk factor (i.e., subclinical organ 96 damage, diabetes, renal, or associated cardiovascular disease)<sup>[20]</sup> and initiated first-line antihypertensive 97 drugs. Each patient record consists of demographics (e.g., age and sex), co-morbidities (via ICD-9/10 98 diagnosis codes) as well as co-prescribed medications (using national drug codes [NDC]). For uniformity, 99 ICD-9/10 codes were consolidated into a standardized coding schema using the clinical classifications 100 software (CCS)<sup>2</sup>. Figure 2 displays the dataset's statistics including the distribution of overall population, 101 age, gender, and outcome across different drug combinations, respectively. Figure 3 illustrates the de-102 tailed study design for each treatment cohort, including treatment definitions, computation of confounding 103 variables, and outcomes. The flowchart of the user cohort selection is provided in Appendix Fig. A1. 104

**Treatments.** Following hypertension management guidelines<sup>[3]</sup>, we categorized first-line antihypertensive 105 agents into thiazide diuretics (TZDs), ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and 106 calcium channel blockers (CCBs). We identified five distinct first-line drug combination regimens, each 107 comprising two different classes: (1) TZDs and ACEIs; (2) TZDs and ARBs; (3) TZDs and CCBs; (4) 108 ACEIs and CCBs; (5) ARBs and CCBs. We note that ACEIs and ARBs are not combined in clinical 109 practice. These combinations also varied by assignment order: initial combination (less than 30 days 110 between first and second drug initiations) and stepped-care (between 30 and 180 days). We identified 111 a total of 15 unique drug combinations, considering both the specific combinations and their order of 112 assignment. Detailed definitions of these drugs are provided in Appendix Table A2. 113

**Outcomes.** Six important outcomes are computed during the follow-up period after the treatment initialization, including three primary effectiveness outcomes (stroke, acute myocardial infarction [MI], heart failure [HF]) and three safety outcomes (acute kidney failure [AKF], gout, venous thromboembolism [VTE]). These outcomes are chosen based on their significance in hypertension management guidelines<sup>3</sup> and insights from recent large-scale studies in hypertension<sup>6</sup>. Outcome occurrences are identified using diagnosis codes, with detailed definitions available in Appendix Table A3.

**Confounders.** A comprehensive list of potential confounders is compiled, including demographics (age and gender), 282 unique co-morbidities (based on diagnosis codes), and 1,378 unique co-prescribed medications. These confounders, relevant to both treatment assignment and outcomes, are assessed during the baseline period before treatment initiation.

# 124 Baselines and Setup

<sup>125</sup> In the experiments, we compare our method with state-of-the-art baselines, which can be classified into <sup>126</sup> three main categories:

• *Basic meta-learners*: (1) **S-learner** is a meta-learner<sup>21</sup> that builds a binary outcome prediction model for all treatment groups; (2) **T-learner** is also a meta-learner<sup>21</sup> that builds multiple outcome prediction models for each treatment group separately.

• *TEE methods for binary treatments and binary outcomes*: (1) **TARNet**<sup>®</sup> predicts the potential outcomes based on balanced representations between treated and controlled groups; (2) **DragonNet**<sup>®</sup> jointly predicts treatment and outcomes based on the shared representations via a three-head neural network.

TEE methods for multiple treatments and binary (multiple) outcomes: (1) PerfectMatch<sup>[11]</sup> augments samples within a batch with their propensity-matched nearest neighbors. The framework can be naturally extended to multiple treatments by matching with the nearest neighbors from each treatment group;
 (2) TECE-VAE<sup>[16]</sup> incorporates latent variables and causal structure through a variational autoencoder,

<sup>&</sup>lt;sup>1</sup>https://www.merative.com/real-world-evidence <sup>2</sup>https://hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

and models multiple treatments with a task embedding; (3) MEMENTO<sup>[13]</sup> is a direct extension of TAR-137 Net<sup>8</sup> to multiple treatments by increasing the number of model branches to the number of treatments; 138 (4) LR-learner<sup>[22]</sup> adopts a neural network to learn embeddings for individuals and treatments, which 139 are then transformed by a linear operator to predict outcomes based on the dot product of these em-140 beddings; (5) TransTEE<sup>115</sup> embeds multiple treatments and covariates into a shared hidden space via a 141 Transformer to improve the model's flexibility and robustness; (6) NCORE<sup>[12]</sup> models the cross-treatment 142 interactions by encoding each treatment arm separately and then applying a merge layer to connect all 143 the treatment arms. 144

Note that we implement the S-learner and T-learner with a logistic regression (LR)-based estimator. TAR-Net<sup>®</sup> and DragonNet<sup>®</sup> are representative works in TEE but initially designed for binary treatment scenarios. We extend these two methods to multiple treatment scenarios as done in<sup>[11]</sup>. For baselines originally developed for binary outcomes, we have facilitated their application to multiple outcome contexts by transitioning from a binary classification head to one capable of multi-label classification.

**Evaluation Metrics** We evaluate the performance of factual outcome prediction by measuring the area 150 under the Precision-Recall curve (AUPR), focusing on the precision-recall trade-off due to the potential 151 imbalance between positive and negative outcome labels. As the ground truth treatment effects are not 152 observed (i.e., any patient is ever only assigned to one of the treatments in practice), we can not di-153 rectly compute the traditional metric precision in estimating heterogeneous effects (PEHE)<sup>[23]</sup>. Instead, we 154 adopt a recent proxy metric for counterfactual evaluation, called influence function-based precision of esti-155 mating heterogeneous effects (IF-PEHE)<sup>24</sup>, which measures the mean squared error between estimated 156 treatment effects and approximated true treatment effects (see detailed computation of IF-PEHE [IP] in 157 Appendix C.2). The original metric is designed for binary treatments and binary outcomes, we extend it 158 to multiple treatments and multiple outcomes (MM-IP) as below: 159

$$\frac{1}{U}\sum_{u} \left[ \frac{1}{|\mathcal{A}| \times |\mathcal{O}|} \sum_{\substack{i,j,q,r \in \mathcal{A} \\ o,s \in \mathcal{O}}} \mathsf{IP}[\hat{\tau}_k^u(\boldsymbol{a}_{i,j}^o, \boldsymbol{a}_{q,r}^s), \tau_k^u(\boldsymbol{a}_{i,j}^o, \boldsymbol{a}_{q,r}^s)] \right]$$
(1)

where U is the total number of patients,  $\tau_k^u$  denotes the treatment effect for patient u on outcome k.

**Implementation Details** The dataset is randomly split into training, validation, and test sets with percent-161 ages of 80%, 10%, and 10% respectively. The number of training epochs is 10 and the learning rate 162 is 5e-5. The backbone model architecture is a 12-layer Transformer, with 768 hidden units, 12 attention 163 heads, and 3072 for the intermediate size. The parameter  $\beta$  in multi-treatment modeling is set to 0.6. The 164 parameter  $\eta$  in outcome type-informed prediction is set to 1 for the training and 0 for the inference. The 165 parameter  $\lambda$ , which adjusts the influence of treatment prediction, is set to 1. All results are reported on the 166 test sets over 20 initializations of the model. More implementation details including the parameter tuning, 167 training setup, and additional configurations are mentioned in Appendix C.3. 168

## **169** Overall Performance Comparison

Results in Table 1 present a comparative evaluation of our proposed METO's performance against base lines in factual outcome prediction and TEE on the real-world hypertension dataset. Notably, METO
 achieves superior performance over the best baseline, registering an average improvement of 5.0% in
 AUPR and 6.4% in MM-IP.

The basic meta-learners, namely the S-learner and T-learner, exhibit diminished performance in comparison to advanced deep learning-based TEE approaches. This discrepancy is attributed to their inability to adequately process high-dimensional, heterogeneous patient data and to forge precise patient representations for accurate effect estimation. While deep learning-based methods for binary treatment and outcome scenarios, such as TARNet, show marginal enhancements over meta-learners, they fall short in addressing the intricacies of multiple treatments and outcomes.

Methods designed for multiple treatments, like PerfectMatch and MEMENTO, offer advancements over
 binary treatment and outcome frameworks. However, their rigid model architectures limit their adaptability

and generalizability across diverse treatment interactions, rendering their performance inferior to more 182 flexible approaches like TECE-VAE, LR-learner, and TransTEE, which are tailored for complex treatment 183 and outcome mappings. 184

The exceptional efficacy of **METO** is attributed to two main strategies: Firstly, the incorporation of a 185 multi-treatment encoding module for the explicit encoding of multiple treatments, including the specifics 186 of drug combinations and their administration sequencing. This approach is finely tuned to address 187 the real-world complexities encountered with antihypertensive drugs and their combinatory uses. Sec-188 ondly, **METO** distinctively models varying types of outcomes—distinguishing therapeutic effectiveness 189 from safety outcomes through the proposed outcome type-informed prediction. By acknowledging the 190 inherent differences in their practical implications and the variability in their distribution across the popula-191 tion, our method adeptly navigates the dual objectives of optimizing disease progression while mitigating 192 safety risks. 193

#### Population Outcome Comparison 194

We hypothesize that the drug combination recommended by our model based on the estimated treatment 195 effects can effectively prevent the patients from developing severe disease outcomes. To demonstrate 196 this, we compare the prevalence of different disease outcomes against two patient treatment groups: 197 1) model-recommended treatment and 2) actual treatment (different from the model's recommendation). 198 Specifically, we first obtain a group of patients whose actual treatment is different from the model's rec-199 ommendation. Then we derive a comparison group by involving the most similar patients whose actual 200 treatment matches the model recommendation. We use the baseline patient representations to calculate 201 the similarity via Euclidean distance. Finally, we compute and compare the prevalence of each disease 202 outcome in Fig. 4. We observe that, for a given outcome, the prevalence rate in patients who receive 203 treatments that are different from our recommendation is higher than the average rate baseline, while the 204 prevalence rate of patients who receive the same treatments as our recommendation is lower than the 205 baseline. This illustrates that our model recommends effective treatment strategies (reflecting on lower 206 prevalence rate on all outcomes), and provides potential clinical insights for doctors to decide the optimal 207 drug combinations for patients with hypertension. 208

#### Ablation Study 209

To demonstrate the significance of individual components within our model, we conducted a compre-210 hensive ablation study. We explore the performance impact of various model configurations, including 211 (1) w/o MT, where the multi-treatment (MT) encoding module is substituted with a generic embedding 212 layer; (2) w/o TC-A, which replaces the treatment-covariate co-attention (TC-CoA) with an average pool-213 ing approach; (3) w/o MT and TC-A, which removes both the MT encoding and TC-CoA to understand 214 the combined effect of these two components; (4) w/o OT, omitting the informative outcome types (OT) in 215 multi-outcome prediction; (5) w/o OC-A, while replaces the outcome-distinctive covariate attention (OC-A) 216 with an average pooling layer. (6) w/o OT and OC-A removes both the OT information and TC-CoA. 217

The results in Fig. 5 present model superiority across various configurations. Notably, the w/o MT 218 and TC-A variant exhibits the most significant performance drop, underscoring the critical role of multi-219 treatment encoding and treatment-covariate co-attention in effectively capturing the nuanced relationships 220 between treatments and covariates. Similarly, the w/o OT and OC-A configuration shows a marked de-221 crease in performance, highlighting the value of incorporating outcome types and the outcome-distinctive 222 covariate attention mechanism for enhanced prediction accuracy. 223

Further comparisons with nuanced model variants reveal the significance of each individual compo-224 nent to model performance. For example, w/o TC-A, w/o OC-A, which employ average pooling instead of 225 the specialized attention mechanisms, reveal that our proposed attention-based approach is more adept 226 at modeling the intricate interplay among covariates, treatments, and outcomes. This finding affirms the 227 attention mechanism's capability to refine TEE by accurately encoding complex relationships within the 228 data. This ablation study not only confirms the integral role of each proposed component in bolstering 229 model performance but also emphasizes the architecture's holistic design in addressing the challenges 230

of TEE with multiple treatments and multiple outcomes. Additional ablation study on propensity score 231 weighting is provided in Appendix Table A7. 232

#### Case Study 233

Treatment Recommendation. Identifying optimal antihypertension drug combinations is inherently com-234 plex due to the multiple available treatments, various drug combinations, multiple patient outcomes, and 235 patient heterogeneity. Our model addresses this complexity by providing a comprehensive clinical out-236 come assessment tool that evaluates the effects of various drug combinations on both therapeutic effec-237 tiveness and safety outcomes. Through a detailed case study depicted in Fig. 6, we demonstrate the 238 practical application of our model in guiding antihypertensive treatment decisions. Within this framework, 239 a patient's medical record is analyzed to estimate the effects of all potential drug combinations. These 240 estimates are then prioritized according to their effectiveness, with a simultaneous assessment of associ-241 ated safety risks, providing a comprehensive overview for clinical review. In the illustrated case, the model 242 identified the combination of TZDs and ACEIs initiated simultaneously as the strategy offering the most 243 significant therapeutic benefit and minimum safety concerns. This finding exemplifies the model's ability to 244 recommend treatment plans that optimize for both efficacy and safety, presenting a valuable assessment 245 and decision-support tool for clinicians. 246

Attention Visualization. For investigating the effect of outcome-distinctive covariate attention, we visu-247 alize the attention weights on the patient pre-treatment covariates using a heatmap in Fig. 7. It presents 248 the top 20 covariates ranked by the learned attention weights of a patient who was prescribed ACEIs 249 and CCBs as initial combination therapy and subsequently developed HF and VTE during their disease 250 progression. This heatmap visualization elucidates the distinct and shared covariate relevancies across 251 the two outcome categories, highlighting how certain conditions such as "respiratory failure; insufficiency; 252 arrest" and "pulmonary heart disease" have high relevance for both HF and VTE. Conversely, specific 253 conditions like "coagulation and hemorrhagic disorders" show a pronounced association primarily with 254 VTE, reflecting the model's nuanced understanding of different mechanisms of effectiveness and safety 255 outcomes. This analysis confirms the capability of the proposed attention networks to dynamically con-256 centrate on both unique and shared information pertinent to patient outcomes. By effectively capturing 257 and modeling the intricate relationships between various covariates and outcomes, attention mechanisms 258 play a crucial role in enhancing the model's predictive accuracy in TEE, thereby supporting personalized 259 treatment strategies. 260

#### Discussion 261

In this paper, we studied the problem of treatment effect estimation in the complex context of hypertension 262 management, characterized by multiple drug combinations and multiple outcomes. We proposed **METO**, 263 an innovative methodology designed to address these complexities. **METO** employs multi-treatment en-264 coding to unravel the intricacies of various drug combinations and leverages outcome type information to 265 better differentiate between effectiveness and safety outcomes. Validated by extensive experiments on a 266 real-world dataset, **METO** demonstrates superior performance compared to traditional TEE methods. By 267 offering a more comprehensive treatment effect assessment for antihypertensive drugs, **METO** makes a 268 substantial contribution to improving patient care in the field of hypertension management. 269

**TEE under Multiple Treatments.** Traditional TEE research is largely anchored in binary treatment and 270 binary outcome scenarios<sup>8-10/25-28</sup>, posing challenges when extending to accommodate the complexity 271 of real-world healthcare scenarios involving multiple treatments and multiple outcomes. Though some 272 studies<sup>11H13</sup> have been proposed to specifically address the challenges of multiple treatments, they often 273 face computational inefficiencies and less flexibility. For instance, MEMENTO<sup>[13]</sup>, which is a direct exten-274 sion of a traditional TEE method (TARNet<sup>®</sup>), assigns covariates from different treatment groups to different 275 branches in their model. This approach can be less flexible with varying numbers of treatments. Meth-276 ods<sup>[15]16]22]</sup> that encode multiple treatments into a hidden embedding space offer some improvements in 277 modeling flexibility. TECE-VAE<sup>116</sup>, for instance, incorporates latent variables and causal structure through 278

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

a variational autoencoder (VAE), and models multiple treatments with a task embedding. However, all
these methods still fall short of fully capturing the complexities of multiple treatments in real applications,
where the treatment can be a drug combination with different administration sequences, thus leading to
an insufficient understanding of treatments and suboptimal model performance.

TEE under Multiple Outcomes. Recent approaches 17-19/22/29 have attempted to address TEE under 283 multiple outcome scenarios. For example, Kennedy et al.<sup>17</sup> propose to translate the treatment effects of 284 multiple outcomes to a common scale and then estimate these scaled effects with non-parametric statis-285 tical methods. Argaw et al.<sup>19</sup> examine the heterogeneous treatment effects and identify patient subpop-286 ulations under multiple outcomes. However, most methods are designed and evaluated on randomized 287 controlled trial data (e.g., A/B testing) without the consideration of confounding bias (i.e., non-randomized 288 treatment assignment) that widely exists in observational patient data. More importantly, a crucial aspect 289 in our context is the differentiation between types of outcomes: therapeutic effectiveness versus safety 290 endpoints. The omission of this distinction in current methodologies can lead to inaccuracies in outcome 291 prediction and failure to identify optimal treatment strategies that consider both aspects. 292

Covariate Balancing Assessment. In observational studies, it is crucial to ensure that the treatment 293 groups are comparable with respect to baseline characteristics. We achieve this through propensity 294 weighting, which reduces potential confounding by re-weighting each individual based on the propensity 295 score. We compare the covariate balancing of the unweighted (original) and weighted data with absolute 296 standard mean difference (ASMD). The ASMD is a widely used metric in propensity score analysis, quan-297 tifying the difference in means (or proportions) of a covariate between treatment groups, standardized 298 by the pooled standard deviation. An ASMD of 0.1 or less is generally considered to indicate adequate 299 balance. We follow existing work<sup>[30]</sup> to calculate the ASMD of a target treatment against the remaining 300 treatments. Figure 8 presents the ASMD of drug combination cohort "TZDs + ACEIs" for a variety of 301 covariates, including demographic factors (e.g., age), clinical diagnoses (e.g., thyroid disorders, diabetes 302 mellitus with complications), and medications (e.g., furosemide, metformin). In the unweighted original 303 data, several covariates exhibit ASMDs greater than the 0.1 threshold, indicating a significant imbalance. 304 After re-weighting the population, the ASMDs for most covariates are reduced and fall below the 0.1 305 threshold, demonstrating improved balance. This enhanced balance demonstrates that the confound-306 ing bias is mitigated, ensuring the accuracy of estimated treatment effects. A comprehensive covariate 307 balancing plot for all covariates is provided in Appendix Fig. A2 308

**Results on Semi-Synthetic Data.** Since ground truth treatment effects are unavailable in observational data (i.e., only one of the potential outcomes can be observed), direct evaluation of model performance for estimation accuracy is not possible. To address this limitation, we conducted experiments on semisynthetic data with simulated true treatment effects. Specifically, treatment assignments and outcomes were simulated based on real patient covariates (details provided in Appendix D.1). Comparative results are presented in Appendix Table A5, showing that the proposed model achieves the highest performance across all baselines on the semi-synthetic data.

Potential trade-offs among outcomes. In our paper, we consider multiple disease outcomes and iden-316 tify the optimal drug combination as one that achieves both maximum effectiveness and minimal safety 317 risks. However, there are potential trade-offs among outcomes, particularly in cases where the treat-318 ment option with maximum effectiveness may not align with minimal safety risks. To mitigate this, it is 319 essential to incorporate clinicians' expert knowledge. In real-world clinical settings, clinicians can help 320 determine the relative importance of different outcomes based on their practical experience and model 321 estimated treatment effects. By integrating clinical insights with model outputs, we can carefully assess 322 and prioritize outcomes, ultimately combining them into a single, composite endpoint that balances both 323 effectiveness and safety considerations. This approach allows for the identification of the optimal treat-324 ment option based on its estimated effects on the combined outcome, ensuring that the selected treatment 325 best aligns with the patient's overall needs and preferences. 326

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

**Limitations of the Study** We acknowledge that our paper has limitations. First, from a data perspec-327 tive, the use of observational data presents challenges, primarily due to the absence of ground truths for 328 treatment effects. This lack of true benchmarks makes it difficult to directly evaluate the model's accuracy 329 in estimating treatment effects. To address this limitation, we proposed the use of a proxy metric, MM-330 IP, to approximate estimation error and supplemented our analysis with experiments on a semi-synthetic 331 dataset that includes simulated ground truths. Second, from methodology perspective, in estimating treat-332 ment effects across multiple outcomes and identifying the optimal treatments, potential conflicts among 333 outcomes may arise. We anticipate that, in real clinical settings, incorporating clinicians' expertise as prior 334 knowledge could help guide the process, minimizing conflicts and enabling convergence toward a reliable 335 recommendation. 336

#### Acknowledgments 337

This work was funded in part by the National Institutes of Health (NIH) under award number R01GM141279. 338 The content is solely the responsibility of the authors and does not necessarily represent the official views 339 of the NIH. 340

### Author contributions 341

PZ conceived the project. RL and PZ developed the method. RL conducted the experiments. RL, PZ, 342 and LL analyzed the results. RL and PZ wrote the manuscript. All authors read and approved the final 343 manuscript. 344

#### Declaration of interests 345

The authors declare no competing interests. 346

#### **Resource availability** 347

#### Lead contact 348

Further information and requests for resources should be directed to and will be fulfilled by the lead 349 contact, Dr. Ping Zhang (zhang.10631@osu.edu). 350

#### Data and code availability 351

The data we use is from MarketScan Commercial Claims and Encounters (CCAE) and includes ap-352 proximately 130 million patients from 2012 to 2021. Access to the MarketScan data analyzed in this 353 manuscript is provided by The Ohio State University. The dataset is available at https://www.merative. 354 com/real-world-evidence. The source code for this paper can be downloaded from the GitHub reposi-355 tory at https://github.com/ruoqi-liu/METO. 356

#### Methods 357

In this section, we introduce the proposed **METO** framework for treatment effect estimation under multiple 358 treatments and multiple outcomes on observational patient data. Fig. 9 shows an illustration of the 359 proposed framework. Specifically, this framework consists of four modules: patient data encoding, multi-360 treatment modeling, multi-outcome prediction, and treatment recommendation. 361

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

# 362 **Preliminaries**

**Observational Patient Data.** The observational patient data is denoted as  $\{\overline{x}, c, a, y\}$ . Here,  $\overline{x} = \{x^1, \ldots, x^T\}$  represents the patient's medical history over T timestamps, capturing the details of each medical visit. The variable c stands for static demographic information, including age (categorical) and gender (binary). Each medical visit,  $x^t$ , contains a series of medications and diagnosis codes. Specifically, medications are represented as  $m_1, \ldots, m_{|\mathcal{M}|} \in \mathcal{M}$ , where  $|\mathcal{M}|$  is the total number of unique medication codes in the dataset. Similarly, diagnosis codes are denoted as  $d_1, \ldots, d_{|\mathcal{D}|} \in \mathcal{D}$ , with  $|\mathcal{D}|$  representing the total number of unique diagnosis codes.

**Multiple Treatments.** This work studies multiple treatment scenarios for antihypertensive drug combinations. Each drug combination is represented as  $a_{i,j}^o$ , where  $(a_i, a_j, o)$  denotes individual drugs  $a_i$ ,  $a_j$ from the antihypertensive medication set A, and  $o \in O$  of the treatment assignment order. This order includes initial combination therapy (simultaneous administration of  $a_i$  and  $a_j$ ) and stepped-care protocols (sequential administration of  $a_i$  followed by  $a_j$ , or vice versa). Let P denote the total number of unique drug combinations.

Multiple Outcomes. The investigation extends to multiple outcomes,  $y = y_1, ..., y_K$ , where each outcome  $y_k$ , binary in nature, relates to a specific aspect of hypertension disease progression. Here, Kdenotes the total number of distinct outcomes. Each outcome  $y_k$  is also associated with a type label  $g_k$ , categorizing it as either an effectiveness outcome or a safety outcome. This classification provides a comprehensive view of the treatment's impact, enabling the assessment of treatment effects from different perspectives.

Treatment Effect Estimation. We extend the Neyman-Rubin potential outcome framework<sup>31</sup> to accom-382 modate multiple treatments and multiple outcomes. Given patient pre-treatment covariates  $\overline{x}$ , c and dis-383 tinct treatment combinations  $a^o_{i,j}$  and  $a^s_{q,r}$  with  $i, j, q, r \in A$  and  $o, s \in O$ , the conditional average treatment 384 effect (CATE) for the k-th outcome is defined as  $\mathbb{E}[y_k(a_{i,j}^o) - y_k(a_{q,r}^s)|\overline{x}, c]$ . This expression considers 385  $y_k(a_{i,i}^o)$  and  $y_k(a_{a,r}^s)$  as the potential outcomes under treatment combinations  $a_{i,i}^o$  or  $a_{a,r}^s$ , respectively. 386 In observational data, outcomes for the non-received treatments remain unobserved, posing the funda-387 mental causal inference challenge, distinct from traditional supervised learning. To ensure identifiability 388 of treatment effects from observational data, we adhere to three standard assumptions: consistency, 389 positivity, and ignorability<sup>32</sup>, as elaborated in Appendix A. Under these premises, the treatment effect is 390 estimated as  $\mathbb{E}[y_k | \boldsymbol{a}_{i,j}^o, \overline{\boldsymbol{x}}, c] - \mathbb{E}[y_k | \boldsymbol{a}_{q,r}^s, \overline{\boldsymbol{x}}, c].$ 391

## 392 Patient Data Encoding

The patient data is originally denoted by high-dimensional medical codes with temporal information. To convert such raw patient data into informative patient representations, we propose patient data encoding, which consists of a visit embedding layer and a time-aware Transformer encoder. Below, we integrate mathematical formulations to elucidate the operations within these components.

Visit Embedding Layer. The visit embedding layer focuses on the patient's covariates in medical history, denoted as  $\overline{x} = \{x^1, \dots, x^T\}$ . Each element  $x^t$  (where  $t \in 1, \dots, T$ ) represents the details of a patient's visit at a specific timestamp. The embedding layer maps these discrete visit records into a continuous vector space, resulting in an embedded representation  $e(x^t)$  for each visit. Formally, the embedding of the *t*-th visit is given by:

$$e(x^t) = \text{VisitEmbeddingLayer}(x^t), \quad \forall t \in 1, \dots, T$$
 (2)

Time-aware Transformer Encoder. To enhance the patient representation, time information is also encoded and integrated with the visit embeddings. Specifically, the time interval ( $v_t$ ) between the *t*-th visit and the initiation of treatment is encoded into a time embedding  $e(v^t)$ , parallel to the visit embeddings as:

$$e(v^t) = \mathsf{TimeEmbeddingLayer}(v^t), \quad \forall t \in 1, \dots, T$$
 (3)

<sup>405</sup> This addition allows the model to account for temporal dynamics explicitly, which are essential in health-<sup>406</sup> care applications. The combined input to the Transformer encoder<sup>[33]</sup> (see details of Transformer layers in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

<sup>407</sup> Appendix **B.1**) consists of both visit and time embeddings. Let  $h^0$  denote the initial hidden representation <sup>408</sup> as below:

$$h^{0} = [e(x^{1}) + e(v^{1}), \dots, e(x^{T}) + e(v^{T}), e(c)]$$
(4)

 $_{409}$  The Transformer processes this enriched input through *L* layers:

$$h^{l} = \text{TransformerEncoderLayer}(h^{l-1}), \quad l \in 1, \dots, L$$
 (5)

The final output  $h^L$  is a comprehensive representation of the patient, effectively capturing both the temporal aspects of the medical history and static demographic information. This encoded information (denoted as *h* for simplicity) is then utilized in subsequent multi-treatment modeling and multi-outcome prediction.

## 413 Multi-Treatment Modeling

This module is designed to address the complexities of multi-treatment modeling, specifically for drug combinations in hypertension management. First, the module encodes multiple drug combinations into latent embeddings. Then, it models the relationships between covariates and treatments to extract treatment-related information. The predicted treatment probability is further utilized as balancing weights to adjust for confounding bias.

Multi-Treatment Encoding. The initial phase of this module focuses on encoding the drug combinations into an embedding space. Given a drug combination  $a_{i,j}^o$ , which includes two individual drugs ( $a_i$  and  $a_j$ ) and their assignment order o, we approach the encoding process in a two-fold manner to capture both the drug-specific information and its sequential information.

Firstly, each drug in the combination,  $a_i$  and  $a_j$ , is encoded separately through a drug embedding layer, which transforms the discrete drug identifiers into continuous vector representations. The embeddings for  $a_i$  and  $a_j$  are obtained as:

$$e(a_i) = \mathsf{DrugEmbeddingLayer}(a_i),$$
  
 $e(a_i) = \mathsf{DrugEmbeddingLayer}(a_i)$ 
(6)

The assignment order *o*, which indicates whether the drugs are administered simultaneously or sequentially, is also encoded. The order encoding captures the temporal aspect of the treatment administration. This is represented as:

$$e(o) = \text{OrderEmbeddingLayer}(o)$$
 (7)

Secondly, to achieve a deep fusion of individual drugs and assignment order for a comprehensive
 treatment representation, we propose a treatment fusion layer:

$$s(a_{i,j}^{o}) = \text{TreatmentFusion}(e(a_i), e(a_j), e(o))$$
 (8)

Specifically, this component first concatenates the drug embeddings with the order embedding and then
 projects this concatenated vector to a latent space through a fully connected layer (FC) for dimensionality
 alignment and feature extraction:

$$\boldsymbol{e}(\boldsymbol{a}_{i,j}^{o}) = \mathsf{FC}([\boldsymbol{e}(a_i), \boldsymbol{e}(a_j), \boldsymbol{e}(o)]) \tag{9}$$

In addition, a self-attention mechanism (multi-head attention mechanism<sup>33</sup>) is applied to weigh and integrate the information from the drug and order embeddings adaptively:

$$s(a_{i,j}^{o}) = \text{SelfAttention}(e(a_{i,j}^{o}))$$
 (10)

**Treatment-Covariate Co-Attention.** This component plays a critical role in modeling the interactions between specific treatments and patient covariates. By considering treatment representation  $s(a_{i,j}^o)$  as "queries" and patient hidden representations h (last hidden state of transformer encoder) as both "keys" and "values", we employ a co-attention mechanism<sup>34</sup> that dynamically adjusts the focus on relevant covariates for each treatment option:

$$h_a = \operatorname{Softmax}\left(s(a_{i,j}^o)h/\sqrt{d_k}\right)h$$
 (11)

#### perpetuity. It is made available under a CC-BY-NC 4.0 International license .

where  $d_k$  is the dimensionality of the key embeddings. This co-attention mechanism allows the model to dynamically focus on different aspects of the patient's representation in relation to each treatment.

**Treatment Prediction.** The pooled patient representation  $h_{pool}$  (i.e., taking the first [CLS] token from h) is processed through a fully-connected layer with a sigmoid activation function  $\sigma$  as the last layer to predict the probability of receiving each treatment  $\hat{a}_{i,j}^o$  as follows:

$$\hat{a}_{i,j}^{o} = \sigma(\mathsf{FC}(\boldsymbol{h}_{pool})) \tag{12}$$

The treatment prediction task is formulated as a multi-class classification problem, where each class corresponds to a specific treatment combination. The treatment prediction loss function is defined as:

$$\mathcal{L}_{\text{treat}} = -\sum_{i,j \in \mathcal{A}, o \in \mathcal{O}} \boldsymbol{a}_{i,j}^{o} \log(\hat{\boldsymbol{a}}_{i,j}^{o})$$
(13)

where  $a_{i,j}^o$  is the ground truth treatment assignment. By minimizing  $\mathcal{L}_{\text{treat}}$ , the model is optimized to predict the probability of receiving each treatment combination.

Propensity Score Weighting. The predicted probability of receiving treatment, also known as the propensity score<sup>35</sup>, is further leveraged to reduce the bias from confounding factors. Specifically, the balancing weights can be derived from the propensity scores and then used to estimate the potential outcomes. The inverse probability of treatment weighting (IPTW)<sup>36</sup> is employed and extended to multiple treatment settings<sup>37</sup> as follows,

$$w = \frac{W(\boldsymbol{a}_{i,j}^{o})}{\hat{\boldsymbol{a}}_{i,j}^{o}}$$
(14)

where  $W(a_{i,j}^o)$  is the marginal probability of treatment  $a_{i,j}^o$  that is included to stabilize the weights. Then the weight is used in the multi-outcome prediction to re-weight the patient and adjust for confounding bias.

### 457 Multi-Outcome Prediction

This module focuses on predicting multiple disease outcomes in a nuanced and comprehensive manner.
 This module first encodes the distinctive relationships among different outcomes and patient covariates
 and then predicts the outcomes, weighted based on the balancing propensity scores.

Outcome-Distinctive Covariate Attention. This component addresses the distinctive impact that patient covariates have on different disease outcomes. It computes an outcome-distinctive covariate attention score  $\alpha \in \mathbb{R}^{K \times N}$  (where *K* is the number of outcomes, and *N* is the length of patient sequence) as follows:

$$\alpha = \operatorname{softmax}(W_2 \tanh(W_1 \tilde{\boldsymbol{h}}^T))$$
  

$$\tilde{\boldsymbol{h}} = \operatorname{MLP}([\boldsymbol{h}_a, \boldsymbol{h}])$$
(15)

where,  $W_1 \in \mathbb{R}^{d_o \times d_h}$  and  $W_2 \in \mathbb{R}^{K \times d_o}$  are trainable weight matrices,  $\alpha_{k,n}$  (each element of  $\alpha$ ) indicates the 465 contribution of the *n*-th covariate to the *k*-th outcome. Leveraging  $\alpha$ , the mechanism produces outcome-466 distinctive patient representations as  $h_o = \alpha h$ , thereby refining the predictions for each distinct outcome. 467 **Re-weighted Multi-outcome Prediction with Type Information.** We recognize the critical role of out-468 come type (i.e., distinguishing between effectiveness and safety) in accurately predicting patient re-469 sponses to treatment. These types embody the dual (opposing) aspects of patient outcomes, each critical 470 to understanding the full scope of treatment impacts. To harness this crucial insight, we propose first to 471 predict each outcome type,  $\hat{g}_k$ , utilizing this prediction to enhance the subsequent outcome prediction,  $\hat{y}_k$ . 472 In a teacher-forcing-like approach, during the training, the model predominantly uses the actual outcome 473 types  $g_k$  as supplementary context for enhancing outcome predictions, while in testing, it relies on its 474 predictive capabilities for  $\hat{g}_k$ . Formally, we have 475

$$\hat{g}_k = \sigma(f_g(\boldsymbol{h}_o)), \quad \hat{y}_k = \sigma(f_\eta(\boldsymbol{h}_o, g_k, \hat{g}_k))$$
(16)

Here,  $f_g$  denotes the function to predict outcome type.  $f_\eta$  is the function to predict the outcome itself, where  $\eta \in [0, 1]$  represents a tunable probability parameter designed to modulate the dependency on true versus predicted outcome types.

#### perpetuity. It is made available under a CC-BY-NC 4.0 International license .

To address the potential issue of positive-negative imbalance encountered in outcome prediction (i.e., where the incidence rate of certain disease outcomes may be notably low), we employ the Asymmetric Loss (ASL)<sup>39</sup>. ASL is adept at handling such imbalances by calculating separate losses for positive and negative samples, denoted as  $\mathcal{L}$ + and  $\mathcal{L}$ -, respectively. The formulation is as follows:

$$\mathcal{L}_{\text{outcome}} = \begin{cases} \mathcal{L}_{+} = w(1-\hat{y})^{\gamma_{+}}\log(\hat{y})\\ \mathcal{L}_{-} = w\hat{y}^{c\gamma_{-}}\log(1-\hat{y}^{c}) \end{cases}$$
(17)

where  $\hat{y}^c = \max(\hat{y}-c, 0)$  represents the adjusted outcome probability for negative examples, incorporating a margin *c* for hard thresholding. The hyperparameters  $\gamma -$ ,  $\gamma +$  are set such that  $\gamma_- \leq \gamma_+$ , enabling ASL to appropriately down-weight and apply hard thresholds to easy negative samples, thereby mitigating the imbalances. The balancing weight, *w* (from Eq. 14), is introduced to adjust the importance of each sample in the loss function based on the treatment assignment probability, which helps to mitigate the bias introduced by the non-random treatment assignment.

**Optimization and Treatment Effect Estimation.** The overall loss function integrates the outcome prediction loss  $\mathcal{L}_{outcome}$  with the treatment prediction loss  $\mathcal{L}_{treat}$  as:

$$\mathcal{L} = \mathcal{L}_{\text{outcome}} + \lambda \mathcal{L}_{\text{treat}}$$
(18)

where  $\lambda$  is a weighting factor that balances the importance of the outcome prediction loss and the treatment prediction loss. This combined loss function ensures that the model is trained to accurately predict both patient outcomes and treatment assignments, reflecting the complex relations of treatments and their effects.

The estimated treatment effect under a pair of treatments  $a_{i,j}^o$  and  $a_{q,r}^s$  is defined as the differential between the potential outcomes:

$$\hat{y}_k(a_{i,j}^o) - \hat{y}_k(a_{a,r}^s), \quad \forall k \in 1, \dots, K$$
(19)

This estimation is essential for elucidating the comparative impact of different treatments, thereby equipping healthcare professionals with the insights needed to make informed treatment selections.

### **499** Treatment Recommendation

This module demonstrates the application of the proposed **METO** in a healthcare problem for antihypertensive drug combination recommendation. Utilizing the estimated treatment effects across diverse drug combinations facilitates the identification of an optimal treatment strategy with maximum therapeutic efficacy and minimum drug safety concerns.

<sup>504</sup> Specifically, the trained model,  $f_{\theta^*}$ , with  $\theta^*$  representing the optimized parameters, is employed to si-<sup>505</sup> multaneously evaluate effectiveness and safety outcomes for each potential treatment regimen concerning <sup>506</sup> a new patient as:

$$\hat{y}_k(\boldsymbol{a}_{i,j}^o) = f_{\theta^*}(\overline{\boldsymbol{x}}, c, \boldsymbol{a}_{i,j}^o), \quad \forall k \in 1, \dots, K$$
(20)

The model evaluates each antihypertensive drug combination  $a_{i,j}^o$  by predicting effectiveness outcomes,  $\hat{y}_{effect}(a_{i,j}^o)$ , and safety outcomes,  $\hat{y}_{safe}(a_{i,j}^o)$ . The therapeutic effectiveness improvement over a baseline, denoted as  $\hat{\tau}_{effect}(a_{i,j}^o) = \hat{y}_{effect}(a_{i,j}^o) - \hat{y}_{base}$ , guides the ranking of treatments. The optimal treatment,  $a_{opt}^*$ , is then identified as the one offering maximal effectiveness improvement while ensuring minimal safety risk:

$$\boldsymbol{a}_{\mathsf{opt}}^* = \operatorname*{argmin}_{i,j \in \mathcal{A}, o \in \mathcal{O}} \hat{y}_{\mathsf{safe}}(\boldsymbol{a}_{i,j}^o) \text{ s.t. } \max_{i,j \in \mathcal{A}, o \in \mathcal{O}} \hat{\tau}_{\mathsf{effect}}(\boldsymbol{a}_{i,j}^o)$$
(21)

<sup>512</sup> This streamlined approach empowers healthcare professionals to tailor treatment plans precisely, balanc-<sup>513</sup> ing efficacy with safety, to meet individual patient needs effectively.

# perpetuity. It is made available under a CC-BY-NC 4.0 International license .

#### References 514

- 1. Rojas Rueda, D. (2017). Global burden of hypertension and systolic blood pressure of at least 110 515 to 115 mm hg, 1990-2015. JAMA, 2017, vol. 317, num. 2, p. 165-182. 516
- 2. Frank, J. (2008). Managing hypertension using combination therapy. American family physician 77, 517 1279-1286. 518
- 3. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Him-519 melfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W. et al. (2018). 2017 520 acc/aha/aapa/abc/acpm/ags/apha/ash/aspc/nma/pcna guideline for the prevention, detection, evalu-521 ation, and management of high blood pressure in adults: a report of the american college of cardi-522 ology/american heart association task force on clinical practice guidelines. Journal of the American 523 College of Cardiology 71, e127–e248. 524
- 4. Mancia, G., Rea, F., Corrao, G., and Grassi, G. (2019). Two-drug combinations as first-step antihy-525 pertensive treatment. Circulation research 124, 1113-1123. 526
- 5. Lu, Y., Van Zandt, M., Liu, Y., Li, J., Wang, X., Chen, Y., Chen, Z., Cho, J., Dorajoo, S. R., Feng, M. 527 et al. (2022). Analysis of dual combination therapies used in treatment of hypertension in a multina-528 tional cohort. JAMA network open 5, e223877-e223877. 529
- 6. Suchard, M. A., Schuemie, M. J., Krumholz, H. M., You, S. C., Chen, R., Pratt, N., Reich, C. G., Duke, 530 J., Madigan, D., Hripcsak, G. et al. (2019). Comprehensive comparative effectiveness and safety of 531 first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet 532 394, 1816-1826. 533
- 7. Berkey, C., Anderson, J., and Hoaglin, D. (1996). Multiple-outcome meta-analysis of clinical trials. 534 Statistics in medicine 15, 537-557. 535
- 8. Shalit, U., Johansson, F. D., and Sontag, D. A. (2017). Estimating individual treatment effect: 536 generalization bounds and algorithms. In: Precup, D., and Teh, Y. W., eds. Proceedings of the 537 34th International Conference on Machine Learning, ICML 2017, Sydney, NSW, Australia, 6-11 538 August 2017 vol. 70 of Proceedings of Machine Learning Research. PMLR (3076-3085). URL: 539 http://proceedings.mlr.press/v70/shalit17a.html. 540
- 9. Shi, C., Blei, D. M., and Veitch, V. (2019). Adapting neural networks for the estimation of treat-541 ment effects. In: Wallach, H. M., Larochelle, H., Beygelzimer, A., d'Alché-Buc, F., Fox, E. B., 542 and Garnett, R., eds. Advances in Neural Information Processing Systems 32: Annual Confer-543 ence on Neural Information Processing Systems 2019, NeurIPS 2019, December 8-14, 2019, Van-544 couver, BC, Canada. (2503-2513). URL: https://proceedings.neurips.cc/paper/2019/hash/ 545 8fb5f8be2aa9d6c64a04e3ab9f63feee-Abstract.html. 546
- 10. Curth, A., and van der Schaar, M. (2021). Nonparametric estimation of heterogeneous treatment 547 effects: From theory to learning algorithms. In: Banerjee, A., and Fukumizu, K., eds. The 24th 548 International Conference on Artificial Intelligence and Statistics, AISTATS 2021, April 13-15, 2021, 549 Virtual Event vol. 130 of Proceedings of Machine Learning Research. PMLR (1810–1818). URL: 550 http://proceedings.mlr.press/v130/curth21a.html. 551
- 11. Schwab, P., Linhardt, L., and Karlen, W. (2018). Perfect match: A simple method for learning repre-552 sentations for counterfactual inference with neural networks. ArXiv preprint abs/1810.00656. URL: 553 https://arxiv.org/abs/1810.00656. 554

<sup>12.</sup> Parbhoo, S., Bauer, S., and Schwab, P. (2021). Ncore: Neural counterfactual representation learn-555 ing for combinations of treatments. ArXiv preprint abs/2103.11175. URL: https://arxiv.org/abs/ 556 2103.11175. 557

- 13. Mondal, A., Majumder, A., and Chaoji, V. (2022). Memento: Neural model for estimating individual 558 treatment effects for multiple treatments. In: Proceedings of the 31st ACM International Conference 559 on Information & Knowledge Management. (3381-3390). 560
- 14. Chu, Z., Rathbun, S. L., and Li, S. (2022). Multi-task adversarial learning for treatment effect estima-561 tion in basket trials. In: Conference on health, inference, and learning. PMLR (79–91). 562
- 15. Zhang, Y.-F., Zhang, H., Lipton, Z. C., Li, L. E., and Xing, E. P. (2022). Can transformers be strong 563 treatment effect estimators? ArXiv preprint abs/2202.01336. URL: https://arxiv.org/abs/2202. 564 01336. 565
- 16. Saini, S. K., Dhamnani, S., Srinivasan, A., Ibrahim, A. A., and Chavan, P. (2019). Multiple treat-566 ment effect estimation using deep generative model with task embedding. In: Liu, L., White, R. W., 567 Mantrach, A., Silvestri, F., McAuley, J. J., Baeza-Yates, R., and Zia, L., eds. The World Wide Web 568 Conference, WWW 2019, San Francisco, CA, USA, May 13-17, 2019. ACM (1601-1611). URL: 569 https://doi.org/10.1145/3308558.3313744.doi 10.1145/3308558.3313744. 570
- 17. Kennedy, E. H., Kangovi, S., and Mitra, N. (2019). Estimating scaled treatment effects with multiple 571 outcomes. Statistical methods in medical research 28, 1094–1104. 572
- 18. Yuki, S., Tanioka, K., and Yadohisa, H. (2021). Estimation and visualization of treatment effects for 573 multiple outcomes. ArXiv preprint abs/2108.00163. URL: https://arxiv.org/abs/2108.00163. 574
- 19. Argaw, P. N., Healey, E., and Kohane, I. S. (2022). Identifying heterogeneous treatment effects in 575 multiple outcomes using joint confidence intervals. In: Machine Learning for Health. PMLR (141-576 170). 577
- 20. Sever, P. S., and Messerli, F. H. (2011). Hypertension management 2011: optimal combination ther-578 apy. European heart journal 32, 2499-2506. 579
- 21. Künzel, S. R., Sekhon, J. S., Bickel, P. J., and Yu, B. (2019). Metalearners for estimating heteroge-580 neous treatment effects using machine learning. Proceedings of the national academy of sciences 581 116, 4156-4165. 582
- 22. Yao, L., Lo, C., Nir, I., Tan, S., Evnine, A., Lerer, A., and Peysakhovich, A. (2022). Efficient heteroge-583 neous treatment effect estimation with multiple experiments and multiple outcomes. ArXiv preprint 584 abs/2206.04907. URL: https://arxiv.org/abs/2206.04907. 585
- 23. Hill, J. L. (2011). Bayesian nonparametric modeling for causal inference. Journal of Computational 586 and Graphical Statistics 20, 217-240. 587
- 24. Alaa, A. M., and van der Schaar, M. (2019). Validating causal inference models via influence func-588 tions. In: Chaudhuri, K., and Salakhutdinov, R., eds. Proceedings of the 36th International Confer-589 ence on Machine Learning, ICML 2019, 9-15 June 2019, Long Beach, California, USA vol. 97 of 590
- Proceedings of Machine Learning Research. PMLR (191-201). URL: http://proceedings.mlr. 591 press/v97/alaa19a.html. 592
- 25. Johansson, F. D., Shalit, U., and Sontag, D. A. (2016). Learning representations for counter-593 factual inference. In: Balcan, M., and Weinberger, K. Q., eds. Proceedings of the 33nd Inter-594 national Conference on Machine Learning, ICML 2016, New York City, NY, USA, June 19-24, 595 2016 vol. 48 of JMLR Workshop and Conference Proceedings. JMLR.org (3020-3029). URL: 596 http://proceedings.mlr.press/v48/johansson16.html. 597
- 26. Yao, L., Li, S., Li, Y., Huai, M., Gao, J., and Zhang, A. (2018). Representation learning for treatment 598 effect estimation from observational data. In: Bengio, S., Wallach, H. M., Larochelle, H., Grauman, 599 K., Cesa-Bianchi, N., and Garnett, R., eds. Advances in Neural Information Processing Systems 31: 600 Annual Conference on Neural Information Processing Systems 2018, NeurIPS 2018, December 3-601 8, 2018, Montréal, Canada. (2638–2648). URL: https://proceedings.neurips.cc/paper/2018/ 602 hash/a50abba8132a77191791390c3eb19fe7-Abstract.html. 603

- 27. Hassanpour, N., and Greiner, R. (2020). Learning disentangled representations for counterfac-604 tual regression. In: 8th International Conference on Learning Representations, ICLR 2020, Addis 605 Ababa, Ethiopia, April 26-30, 2020. OpenReview.net. URL: https://openreview.net/forum?id= 606 HkxBJT4YvB. 607
- 28. Curth, A., and van der Schaar, M. (2021). On inductive biases for heterogeneous treat-608 ment effect estimation. In: Ranzato, M., Beygelzimer, A., Dauphin, Y. N., Liang, P., and 609 Vaughan, J. W., eds. Advances in Neural Information Processing Systems 34: Annual Con-610 ference on Neural Information Processing Systems 2021, NeurIPS 2021, December 6-14, 611 URL: https://proceedings.neurips.cc/paper/2021/hash/ 2021, virtual. (15883–15894). 612 8526e0962a844e4a2f158d831d5fddf7-Abstract.html 613
- 29. Wu, H., Tan, S., Li, W., Garrard, M., Obeng, A., Dimmery, D., Singh, S., Wang, H., Jiang, D., and 614 Bakshy, E. (2022). Interpretable personalized experimentation. In: Proceedings of the 28th ACM 615 SIGKDD Conference on Knowledge Discovery and Data Mining. (4173–4183). 616
- 30. McCaffrey, D. F., Griffin, B. A., Almirall, D., Slaughter, M. E., Ramchand, R., and Burgette, L. F. 617 (2013). A tutorial on propensity score estimation for multiple treatments using generalized boosted 618 models. Statistics in medicine 32, 3388–3414. 619
- 31. Rubin, D. B. (2005). Causal inference using potential outcomes: Design, modeling, decisions. Jour-620 nal of the American Statistical Association 100, 322-331. 621
- 32. Imbens, G. W., and Rubin, D. B. Causal inference in statistics, social, and biomedical sciences. 622 Cambridge University Press (2015). 623
- 33. Vaswani, A., Shazeer, N., Parmar, N., Uszkoreit, J., Jones, L., Gomez, A. N., Kaiser, L., and Polo-624 sukhin, I. (2017). Attention is all you need. In: Guyon, I., von Luxburg, U., Bengio, S., Wallach, H. M., 625 Fergus, R., Vishwanathan, S. V. N., and Garnett, R., eds. Advances in Neural Information Process-626 ing Systems 30: Annual Conference on Neural Information Processing Systems 2017, December 627 4-9, 2017, Long Beach, CA, USA. (5998-6008). URL: https://proceedings.neurips.cc/paper/ 628 2017/hash/3f5ee243547dee91fbd053c1c4a845aa-Abstract.html.
- 34. Murahari, V., Batra, D., Parikh, D., and Das, A. (2020). Large-scale pretraining for visual dialog: A 630 simple state-of-the-art baseline. In: European Conference on Computer Vision. Springer (336–352). 631

629

- 35. Rosenbaum, P. R., and Rubin, D. B. (1983). The central role of the propensity score in observational 632 studies for causal effects. Biometrika 70, 41-55. 633
- 36. Hirano, K., Imbens, G. W., and Ridder, G. (2003). Efficient estimation of average treatment effects 634 using the estimated propensity score. Econometrica 71, 1161–1189. 635
- 37. Austin, P. C. (2018). Assessing the performance of the generalized propensity score for estimating 636 the effect of quantitative or continuous exposures on binary outcomes. Statistics in medicine 37, 637 1874-1894. 638
- 38. Xu, S., Ross, C., Raebel, M. A., Shetterly, S., Blanchette, C., and Smith, D. (2010). Use of stabilized 639 inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. 640 Value in Health 13, 273-277. 641
- 39. Ridnik, T., Baruch, E. B., Zamir, N., Noy, A., Friedman, I., Protter, M., and Zelnik-Manor, L. (2021). 642 Asymmetric loss for multi-label classification. In: 2021 IEEE/CVF International Conference on Com-643 puter Vision, ICCV 2021, Montreal, QC, Canada, October 10-17, 2021. IEEE (82-91). URL: 644 https://doi.org/10.1109/ICCV48922.2021.00015 doi:10.1109/ICCV48922.2021.00015. 645
- 40. Chen, T., and Guestrin, C. (2016). Xgboost: A scalable tree boosting system. In: Krishnapuram, 646 B., Shah, M., Smola, A. J., Aggarwal, C. C., Shen, D., and Rastogi, R., eds. Proceedings of the 647

22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, San Fran-648 cisco, CA, USA, August 13-17, 2016. ACM (785-794). URL: https://doi.org/10.1145/2939672. 649

2939785. doi:10.1145/2939672.2939785. 650

### Main tables and corresponding titles and legends 651

Table 1: Performance comparison for factual outcome prediction (AUPR) and treatment effect estimation (MM-IP: IF-PEHE for multiple treatments and multiple outcomes). The results are averaged over 20 random runs. Full results with standard deviations for all methods are provided in Appendix Table A6

	Method	Stroke		MI		HF		AKF		Gout		VTE	
		AUPR ↑	$MM\text{-}IP\downarrow$										
	S-learner	0.551	0.284	0.188	0.355	0.329	0.378	0.218	0.370	0.339	0.325	0.274	0.356
	T-learner	0.544	0.297	0.181	0.360	0.325	0.386	0.212	0.377	0.331	0.332	0.267	0.363
	TARNet	0.569	0.271	0.196	0.351	0.342	0.357	0.233	0.359	0.349	0.318	0.288	0.355
	DragonNet	0.574	0.262	0.198	0.344	0.351	0.338	0.251	0.342	0.356	0.303	0.294	0.332
	PerfectMatch	0.591	0.239	0.202	0.361	0.388	0.312	0.274	0.331	0.378	0.289	0.312	0.317
	MEMENTO	0.584	0.244	0.208	0.354	0.382	0.317	0.270	0.338	0.372	0.294	0.310	0.322
	TECE-VAE	0.605	0.230	0.211	0.355	0.397	0.302	0.290	0.325	0.381	0.283	0.319	0.309
	LR-learner	0.609	0.225	0.206	0.364	0.392	0.308	0.296	0.321	0.385	0.280	0.326	0.315
	TransTEE	0.617	0.221	0.235	0.321	0.409	0.284	0.303	0.311	0.403	0.261	0.338	0.276
	NCoRE	0.577	0.249	0.207	0.361	0.388	0.313	0.275	0.334	0.370	0.297	0.311	0.326
	METO	0.656	0.185	0.329	0.225	0.442	0.236	0.364	0.238	0.453	0.204	0.363	0.201
	(std)	0.011	0.003	0.009	0.005	0.013	0.004	0.014	0.007	0.007	0.006	0.008	0.003



Figure 1: Workflow overview of the proposed METO. Patient records are extracted from medical claims data and processed to train the model, which learns to estimate the treatment effects of multiple drug combinations. The lower panel shows the model's output, where the estimated effects on both effectiveness and safety outcomes assist clinicians in making informed treatment decisions for hypertension.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 2: Statistics of hypertension patient cohorts across 15 unique drug combinations. (a) Patient population distribution across different drug combinations. (b) Gender distribution across different drug combinations. (c) Age distribution across different drug combinations. (d) Outcome distribution across different drug combinations. TZDs: thiazide diuretics. ACEIs: ACE inhibitors. ARBs: angiotensin receptor blockers. CCBs: calcium channel blockers. + and  $\rightarrow$  denote the initial combination and stepped-care, respectively (e.g., "ACEIs + CCBs" represents the initial combination of ACEIs and CCBs, while "ACEIs  $\rightarrow$  CCBs" represents first ACEIs, then CCBs sequentially). MI: acute myocardial infarction. HF: heart failure. AFK: acute kidney failure. VTE: venous thromboembolism



Figure 3: Illustration of the treatment cohort definitions. The treatment consists of two drugs as a combination. The outcomes are computed in the follow-up period. The pre-treatment covariates obtained from the baseline period are regarded as confounders for adjustment.



Figure 4: Comparison of disease outcomes for different treatment approaches among the patient population. The percentage of patients experiencing specific outcomes across three categories: all patients (dashed line with diamond markers), actual treatments administered (red bars), and model-recommended treatments (blue bars). The error bars on each column indicate the standard errors of the data points.



Figure 5: Ablation study for different variants of METO. The error bars on each column indicate the standard errors of the data points.

Individual Patient	Treatments drug combination	Effectiveness $\max_{\substack{i,j \in \mathcal{A}, o \in \mathcal{O}}} \hat{\tau}_{effect} \left( a_{i,j}^{o} \right)$	$\begin{array}{c} \text{Safety} \\ \min_{i,j \in \mathcal{A}, o \in \mathcal{O}} \widehat{y}_{\text{safe}} \left( a_{i,j}^{o} \right) \end{array}$		
	TZDs+ACEIs (Optimal)	0.042±0.002	0.414±0.001		
METO	CCBs→TZDs	$0.034 {\pm} 0.001$	$0.428 {\pm} 0.004$		
	TZDs→CCBs	$0.031 {\pm} 0.003$	$0.426 {\pm} 0.002$		
	TZDs+ARBs	$0.023 {\pm} 0.002$	$0.422 {\pm} 0.002$		
	ARBs→TZDs	0.016±0.004	$0.431 \pm 0.003$		
Optimal Treatment	ACEIs+CCBs (Actual received)	0.000 + 0.000	0.653±0.006		
©⊘ ⊯	[ <u>∅</u> .⊗  ∞ ⊗				

Figure 6: Illustration of how the proposed METO can be used to assist clinicians decide the personalized optimal drug combination with beneficial effects and reduced safety risks.



Figure 7: Visualization of covariates with largest outcome-distinctive covariate attention ( $\alpha_k$ ) of one patient with two outcomes: HF and VTE.



Figure 8: Performance of covariate balancing of TZDs and ACEIs. The absolute standard mean difference (ASMD) values of the top 20 well-balanced covariates before and after weighting are presented. The vertical dotted red line at 0.10 represents the threshold for balance, with points closer to zero indicating better balance.



Figure 9: A detailed illustration of METO. (1) Patient data encoding: raw patient data is transformed into enriched patient representations. (2) Multi-treatment modeling: drug combinations and administration sequences are encoded, and the probability of receiving each treatment is predicted as balancing scores. (3) Multi-outcome prediction: multiple outcomes are predicted by integrating the patient representations with the treatment representations, re-weighted by the balancing scores. (4) Treatment recommendation: optimal drug combinations are identified based on the estimated treatment effects.